Gene Therapy Cures Sickle Cell in 27 of 28 Patients

For the first time, doctors are using the word "cure" when talking about sickle cell disease, and the results are nothing short of remarkable.

In a clinical trial published in the New England Journal of Medicine, 27 out of 28 patients with severe sickle cell disease experienced no painful crises after receiving a one-time gene editing treatment. The therapy, called reni-cel, edits a patient's own blood-forming stem cells to fix the genetic mutation that causes the disease.

"Our aim has been to achieve a functional cure to help prevent any future damage caused by sickle cell disease, and these latest results are compelling," says Dr. Rabi Hanna, who led the study at Cleveland Clinic Children's. Four of the 28 patients received their treatment at his facility.

The process works by collecting stem cells from patients, editing them using CRISPR technology, then returning the corrected cells to their bodies. Before getting their cells back, patients receive chemotherapy to clear space in their bone marrow. The edited cells then take over, producing healthy blood instead of the sickle-shaped cells that cause so much pain.

The results speak for themselves. Within six months, patients' hemoglobin levels jumped from 9.8 to 13.8 grams per deciliter, nearly matching levels seen in people without the disease. The treatment boosts fetal hemoglobin, which prevents red blood cells from forming the characteristic sickle shape that blocks blood flow.

Sickle cell disease affects around 100,000 Americans, predominantly African Americans. The misshapen blood cells cause severe pain, organ damage, and typically shorten life expectancy to the mid-40s. Until now, the only cure was a risky bone marrow transplant that requires finding a matching sibling donor.

Why This Inspires

This breakthrough changes the game because it uses patients' own cells, eliminating the rejection risks that come with traditional transplants. No waiting for donors. No worrying about compatibility. Just one treatment that could last a lifetime.

The therapy represents years of research finally paying off for families who've watched loved ones suffer through painful crises and hospital stays. Cleveland Clinic's specialized sickle cell center provides comprehensive care from childhood through adulthood, and now they can offer real hope alongside that support.

These 28 patients are proof that gene editing isn't science fiction anymore—it's changing lives right now.